Sentences with phrase «mechanisms of evolution as»

In his view, new characteristics are generated and passed on via epigenetics, subject to the same mechanisms of evolution as those with a purely genetic origin.

«We're trying to identify the mechanisms of evolution as it's occurring in the wild» and translate it into a strategy to save the devils, Jones says.

Not exact matches

«The findings showed no mineralogical evidence for abundant liquid water or its by - products, thus pointing to mechanisms other than the flow of water — such as the freeze and thaw of carbon dioxide frost — as being the major drivers of recent gully evolution,» the team explained in the press release.

His idea is essentially «theistic evolution» — belief that God has established evolution as the mechanism by which He has introduced complexity and diversity into the biological sphere of life on earth.

The change that has come about in theologies that partake of creative and emergent evolution can be described in this way: since mechanism is no longer the base of their evolutionary thinking, idealism is no longer essential as a strategy of thought in resolving the tension between science and faith.

None of that belief was ever predicated on a specific interpretation of Genesis with respect to scientific details, and as such, accepting evolution as a mechanism by which God creates did not alter those beliefs.

Dawkins» special reason for having written this book, as perhaps need not be said, is his own frustration over the sheer number of persons in the world today who continue to refuse to believe either in special evolution or in its entirely immanent causal mechanisms.

I am claiming that the difficulty with most neo-Darwinian discussions of evolution is not merely that its mechanisms are inadequate to account for evolution's «qualitative side» but that these mechanisms will be inadequate so long as they are attached (ad hoc) to a materialistic philosophy.

As one who has studied genetics and mechanisms of evolution for most of her life» evolution by natural selection being the one with which I am most familiar» I can say with a high degree of confidence that Prof. Carlin has no clear idea of what «Darwinism» means.

For example, in criticising Dawkins, he points out that «If every step in the series [of evolution] occurs by chance... the end can not be ordered», apparently unaware that Dawkins does not view evolution as entirely random, but allows for a certain direction, provided by the mechanism of natural selection (p. 51).

The present discussion has dealt with the problem of evolution as one depending wholly on mechanisms and chance.

Their claim is that the appearance of new traits in a population, generally regarded as a first step toward the evolution of new species, can occur by means other than the accumulation of micromutations (i.e., small - scale or highly localized mutations), the classic mechanism by which new traits, and eventually new species, are thought to appear.

With worms as his subjects, he plumbs the cellular mechanisms driving the complex protein interactions regulating lifespan, some of which — remarkably — have been conserved through evolution all the way from his microscopic Caenorhabditis elegans to us.

«Together these studies tell a story about how mushroom - forming fungi evolved a complex mechanism for breakdown of plant cell walls in «white rot» and then cast it aside following the evolution of mycorrhizal associations, as well as the alternative decay mechanism of «brown rot,»» Hibbett said.

The second is more controversial, but has come to be accepted over the past 150 years as the principal mechanism of evolution.

Perhaps the mechanisms that allow collective action among chimpanzees served as building blocks for the subsequent evolution of even more sophisticated cooperation later in human evolution.»

Objecting on both philosophical and empirical grounds, Fodor and Piattelli - Palmarini reject natural selection as the mechanism of adaptive evolution.

«It had not particularly occurred to me as a likely mechanism of venom evolution,» admitted Wolfgang Wüster, a lecturer at Bangor University.

Further investigations could pave the way to a more complete understanding of the genetics and metabolomics of cell growth in yeast and the underlying mechanisms relevant to other settings in which cells face challenging conditions, such as cancer progression and the evolution of drug resistance.

Once the mechanism of laughter was set in place by evolution, the theory goes, it could be hijacked for other purposes: the expression of contempt for out - groups (as the superiority theory of humor claims) or the ventilation of forbidden sexual impulses (the relief theory of humor).

«It is essential to understand the dynamics of cultural inheritance at different temporal and spatial scales, to uncover the underlying mechanisms that drive these dynamics, and to shed light on their implications for our current theory of evolution as well as for our interpretation and predictions regarding human behavior.»

Over the course of evolution, plants have developed mechanisms to adapt to periods of inadequate water, and as any gardener can tell you, some species are better able to handle drought than others.

Darwin further noted that evolution must be gradual, with no major breaks or discontinuities and finally, he reasoned that the mechanism of evolution was natural selection and those four insights serve as the foundation for Darwin's founding of a new branch of the philosophy of science, a philosophy of biology because Darwin introduced history into science.

In terms of the evolution of sociality, we examine underlying physiological and cognitive mechanisms that may explain links between stress, social bonds and cooperation, between non-kin as well as kin.

Using Niko Tinbergen's «four questions» as a guide, we will discuss the evolution of primates and emergence of the social function of the behavior (phylogeny), the development of the behavior during a individual's lifetime (ontogeny), the specific biological and chemical processes and motivations responsible for the behavior (mechanism), and how the behavior increase the fitness of individuals, allowing for its continual selection in primates (adaptive value).

However, several genetic mechanisms — including the evolution of protein - coding sequences and gene duplication, as well as the evolution of regulatory sequences — are sources of variation in all species and contribute to organismal adaptation.

The relationships between these two organisms, detailed in a paper published in Nature Communications, can serve as a valuable model to study the evolution and mechanisms of more complex systems.

«One of the neat things this study shows,» said Cravatt, «is that even for enzyme classes as well studied as the hydrolases, there may still be hidden members that, presumably by convergent evolution, arrived at that basic enzyme mechanism despite sharing no sequence or structural homology.»

The identification of the genetic mechanisms underlying human - specific brain development during evolution will transform our ability to decipher the pathophysiological mechanisms underlying neurodevelopmental disorders affecting humans such as autism or schizophrenia.

While the first role of autophagy is to enfold aging cell parts into vesicles where they can be broken down and recycled, evolution has also put this mechanism to work in controlling fat, or lipid, levels and as a backup system for removing harmful bacteria.

These characterizations are pivotal for endeavors such as searching for Earth - like planets and solar twins, understanding the mechanisms that govern stellar evolution, and tracing the dynamics of our Galaxy.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trmechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trMechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trmechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Our findings place the focus back on bacterial evolution between nasopharyngeal carriage and invasion, or diversity of the host, as likely mechanisms for determining invasiveness.

Moreover, the data can serve as a basis for studies concerning the evolution of signaling mechanisms, as well as can give specific insights into the regulation of basic cellular processes such as polar cell growth, cell expansion, plant morphogenesis and the plants responses to fungal pathogens.

Besides the classic model of new gene evolution through gene duplication and functional divergence, other mechanisms are receiving increasing attention as a source of evolutionary innovation.

The difference between us and our pets is that our pets can't outright tell us that they're in pain - often, the exact opposite is true - they hide all signs of pain as a survival mechanism they developed over thousands of years of evolution to keep weakness hidden from predators and other members of their own colonies, Your pet may tell you in different ways when they are uncomfortable, such as by whining or whimpering, staying too still and showing little interest in what's going on around them, sleeping more than usual, becoming aggressive or intolerant of petting or exercise or even by becoming more active - pacing, circling, wandering - as the pain is too much for them to sit still and rest.

Paul Kuniholm Pauper's diverse artistic practice arises amidst issues such as consumerism, corporatocratic evolution, anthropological inquiry overlain popular culture, psychological therapeutic mechanisms, sound language, noise identity, compensatory behavior and durational Art, often in response to self - instigated antipathy toward social media and media distortion of identity.

As to the theory of evolution — it has been shown to be true repeatedly, and it is the only mechanism that explains the evidence.

This technical document argues that the 2010 Conference of the Parties serving as the Meeting of the Parties to the Kyoto Protocol (CMP) 6 decision to introduce the concept of standardized sectoral baselines into the Clean Development Mechanism (CDM), and extended at CMP 7 in 2011 (Durban, South Africa), could also have a substantial impact on the further evolution of the CDM and its regulation.

For topics where people might have strong opinions for political or ideological reasons, such as vaccination and autism, or human evolution, or climate change, there can be strong psychological defense mechanisms to learning a different point of view.

If you had taken the trouble to read the all the post, you would see that the mechanisms of how innate skepticism detects collective deception, or incorrectly triggers on characteristics that are not indicative of collective deception, are completely independent of what the topics at issue are (i.e. work the same for any), and indeed these detection mechanisms are framed using principles that themselves stem from evolution / cultural evolution (so not from contested topic domains such as CC etc. that I or anyone else agrees or disagrees with).

The problem for Blackmore, as for Dennet, is that whereas the mechanisms of evolution — DNA — has been isolated, the mechanisms by which ideas and culture are transmitted are harder to identify.

Although the chain of the actual physical mechanisms generating these cycles is still obscure, (I have argued in my previous papers that the available climatic data would suggest an astronomical modulation of the cloud cover that would induce small oscillations in the albedo that, consequently, would cause oscillations in the surface temperature also by modulating ocean oscillations), the detected cycles can surely be considered from a purely geometrical point of view as a description of the dynamical evolution of the climate system.

Turnbull and Frydenberg have already any ruled out kind of carbon price, even the emissions intensity mechanism proposed by the Climate Change Authority (of which I'm a member) as an evolution of Direct Action.

At paragraph 26 and 27 the Court substantiates the reasons for this as the fact that the interpretation mechanism would not respond to the evolution of the case - law of the Court of Justice, and furthermore would not cover essential elements of the case - law such as direct effect and primacy.

We first trace the progression of conceptions of resilience, giving attention to their evolution from an early focus on individual traits, to models that viewed resilience as primarily a function of relational processes within and outside the family; to current efforts to move beyond identifying numerous indicators of risk and resilience by instead shedding light on underlying causal mechanisms and processes (Luthar 2006).